

CITATION REPORT

List of articles citing

Clinical pharmacokinetics of paclitaxel

DOI: 10.2165/00003088-199427040-00002
Clinical Pharmacokinetics, 1994, 27, 256-69.

Source: <https://exaly.com/paper-pdf/25258050/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
126	Paclitaxel: a promising addition to the antineoplastic armamentarium. 1995 , 5, 1-5		
125	Schedule-dependent radiation enhancement by paclitaxel with accelerated fractionated radiation in a human squamous carcinoma xenograft. 1996 , 4, 268-274		2
124	Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. 1996 , 73, 522-4		51
123	Review : Cremophor: Pharmacological activity of an "inert" solubiliser. 1997 , 3, 186-192		6
122	Clinical chemistry. 1997 , 69, 165R-229R		77
121	Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. <i>Clinical Pharmacokinetics</i> , 1997 , 32, 210-58	6.2	543
120	Individualization of cancer therapy based on cytochrome P450 polymorphism: a pharmacogenetic approach. 1997 , 23, 321-39		10
119	Practical treatment guide for dose individualisation in cancer chemotherapy. 1998 , 56, 1019-38		68
118	Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies. 1999 , 17, 2213-8		42
117	Localized paclitaxel delivery. 1999 , 183, 85-100		102
116	Adaptation of solid phase extraction to an automated column switching method for online sample cleanup as the basis of a facile and sensitive high-performance liquid chromatographic assay for paclitaxel in human plasma. 1999 , 21, 1025-36		20
115	Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. 1999 , 9, 44-53		8
114	Taxanes: an overview of the pharmacokinetics and pharmacodynamics. 1999 , 54, 22-9		103
113	Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel. 2000 , 82, 1519-27		4
112	Mdr1 transfection causes enhanced apoptosis by paclitaxel: an effect independent of drug efflux function of P-glycoprotein. 2001 , 18, 907-13		9
111	Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study. 2001 , 84, 604-10		28
110	Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. 2001 , 62, 207-12		125

109	Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. 2001 , 85, 242-6		100
108	Paclitaxel inhibits proliferation of cell lines responsible for metal stent obstruction: possible topical application in malignant bile duct obstructions. 2002 , 37, 399-404		49
107	The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. 2002 , 17, 23-33		82
106	Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. <i>Journal of Medicinal Chemistry</i> , 2002 , 45, 2867-76	8.3	165
105	A high-throughput combinatorial approach for the discovery of a cremophor EL-free paclitaxel formulation. 2003 , 20, 1302-8		36
104	Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. 2003 , 20, 24-30		104
103	Pharmacology of anticancer drugs in the elderly population. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 1213-426.2		101
102	Interaction between paclitaxel and warfarin. 2003 , 14, 500		15
101	Cytostatic drugs. 2003 , 26, 490-511		2
100	Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. 2004 , 10, 1289-98		142
99	Pharmacokinetic studies in children with cancer. 2004 , 52, 173-97		35
98	Aqueous N,N-diethylnicotinamide (DENA) solution as a medium for accelerated release study of paclitaxel. 2004 , 15, 527-42		11
97	Taxanes in elderly breast cancer patients. 2004 , 30, 333-42		48
96	Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. 2005 , 16, 243-54		118
95	Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane. <i>Journal of Controlled Release</i> , 2005 , 109, 120-6	11.7	171
94	A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. 2005 , 55, 295-300		39
93	Altered pharmacokinetics of paclitaxel in experimental hepatic or renal failure. 2005 , 22, 228-34		15
92	High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection. 2006 , 6, 2		41

91	Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. 2006 , 62, 56-70	20
90	Platinum-containing cytostatic drugs. 2006 , 2849-2872	
89	Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel. 2007 , 8, 803-15	32
88	Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. 2007 , 13, 3623-9	10
87	International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature. 2007 , 25, 1832-43	180
86	Cancer chemotherapy I: hepatocellular injury. 2007 , 11, 641-62, viii	22
85	Paclitaxel: a review of adverse toxicities and novel delivery strategies. 2007 , 6, 609-21	281
84	A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. 2008 , 50, 788-92	12
83	Effect of extracellular matrix elements on the transport of paclitaxel through an arterial wall tissue mimic. 2008 , 9, 2792-8	21
82	Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. 2009 , 30, 3189-96	114
81	Paclitaxel release from micro-porous PLGA disks. 2009 , 64, 4341-4349	30
80	Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis. 2010 , 1, 511-513	11
79	ET(B) receptor agonist, IRL 1620, does not affect paclitaxel plasma pharmacokinetics in breast tumour bearing rats. 2005 , 57, 869-76	7
78	A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. 2010 , 66, 441-8	8
77	Translational considerations for cancer nanomedicine. <i>Journal of Controlled Release</i> , 2010 , 146, 164-74	11.7 79
76	The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice. 2010 , 31, 5199-207	89
75	The therapeutic efficacy of conjugated linoleic acid - paclitaxel on glioma in the rat. 2010 , 31, 5855-64	62
74	Pancratistatin induces apoptosis in clinical leukemia samples with minimal effect on non-cancerous peripheral blood mononuclear cells. 2010 , 10, 6	23

73	A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. 2010 , 21, 370-375		52
72	Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. <i>Biomedicine and Pharmacotherapy</i> , 2011 , 65, 417-26	7.5	60
71	Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial. 2011 , 68, 827-33		26
70	In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. 2011 , 67, 815-24		38
69	Albendazole sensitizes cancer cells to ionizing radiation. 2011 , 6, 160		42
68	In vivo evaluation of novel chitosan graft polymeric micelles for delivery of paclitaxel. 2011 , 18, 181-9		31
67	Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel. 2012 , 341, 16-23		44
66	Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors. 2012 , 40, 2239-49		2
65	Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity?. 2012 , 18, 4219-21		2
64	Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model. 2012 , 207, 514.e1-7		23
63	Taxol, Camptothecin and Beyond for Cancer Therapy. 2012 , 133-178		3
62	The development and clinical validation of a turbulent-flow liquid chromatography-tandem mass spectrometric method for the rapid quantitation of docetaxel in serum. 2013 , 417, 12-8		9
61	A critical review of lipid-based nanoparticles for taxane delivery. 2013 , 334, 157-75		127
60	The effect of guanidinylation of PEGylated poly(2-aminoethyl methacrylate) on the systemic delivery of siRNA. 2013 , 34, 3120-31		43
59	A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs. 2013 , 11, 243-55		18
58	Enhanced oral bioavailability of paclitaxel by concomitant use of absorption enhancers and P-glycoprotein inhibitors in rats. 2013 , 25, 355-61		5
57	Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study. 2014 , 39, 25-31		23
56	Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC-UV after intravenous administration of its novel liposomal formulation. 2014 , 28, 204-12		13

55	Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. 2015 , 2015, 413076	143
54	Novel dietary lipid-based self-nanoemulsifying drug delivery systems of paclitaxel with p-gp inhibitor: implications on cytotoxicity and biopharmaceutical performance. 2015 , 12, 1809-22	43
53	Platinum-containing cytostatic drugs. 2016 , 810-833	
52	Bilateral Corneal Epithelial Lesions Associated with Paclitaxel. 2016 , 93, 1333-1336	4
51	Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer. 2016 , 111, 577-591	26
50	Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion. 2016 , 95, e5392	14
49	Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer. 2016 , 78, 1101-1111	16
48	Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy. 2016 , 141, 74-82	78
47	CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. 2016 , 22, 278-87	148
46	Paclitaxel: What has been done and the challenges remain ahead. 2017 , 526, 474-495	205
45	Synthesis of poly(1,2-glycerol carbonate)-paclitaxel conjugates and their utility as a single high-dose replacement for multi-dose treatment regimens in peritoneal cancer. 2017 , 8, 8443-8450	13
44	Bcl-2/Bcl-x inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death. 2017 , 14, 903-908	14
43	Cytotoxic Chemotherapy. 2017 , 220-235	
42	Lipid-Based Nanoparticles for Targeted Drug Delivery of Anticancer Drug. 2017 , 287-321	1
41	Estrone-modified pH-sensitive glycol chitosan nanoparticles for drug delivery in breast cancer. 2018 , 73, 400-411	51
40	Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 7-19	6.2 75
39	Species difference in paclitaxel disposition correlated with poor pharmacological efficacy translation from mice to humans. 2018 , 10, 165-174	1
38	On Command Drug Delivery via Cell-Conveyed Phototherapeutics. 2019 , 15, e1901442	11

37	Mortality After Paclitaxel-Coated Device Use in Dialysis Access: A Systematic Review and Meta-Analysis. 2019 , 26, 600-612		27
36	Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer. 2019 , 84, 539-550		5
35	Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. 2019 , 83, 1147-1158		7
34	Chemotherapy in pregnancy: exploratory study of the effects of paclitaxel on the expression of placental drug transporters. 2019 , 37, 1075-1085		8
33	Chemotherapy in chronic kidney disease and dialysis. 2020 , 183-196.e7		
32	Pre-Clinical Investigation of Liquid Paclitaxel for Local Drug Delivery: A Pilot Study. 2020 , 13,		2
31	Hematologic adverse drug reactions leading to hospitalization among cancer patients: A retrospective case-control study. 2020 , 83, 784-790		
30	A systematic review and meta-analysis of the risk of death and patency after application of paclitaxel-coated balloons in the hemodialysis access. 2020 , 72, 2186-2196.e3		8
29	Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model. 2020 , 109, 1615-1622		1
28	A universal drug delivery catheter for the treatment of infrapopliteal arterial disease using liquid therapy. 2020 , 96, 393-401		4
27	Clinical Translation of Self-Assembled Cancer Nanomedicines. 2021 , 4, 2000159		17
26	Toxicity of anticancer drugs in human placental tissue explants and trophoblast cell lines. <i>Archives of Toxicology</i> , 2021 , 95, 557-571	5.8	6
25	Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance. <i>Chemico-Biological Interactions</i> , 2021 , 340, 109448	5	5
24	Carbon Monoxide Inhibits Cytochrome P450 Enzymes CYP3A4/2C8 in Human Breast Cancer Cells, Increasing Sensitivity to Paclitaxel. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 8437-8446	8.3	3
23	Paclitaxel and naringenin-loaded solid lipid nanoparticles surface modified with cyclic peptides with improved tumor targeting ability in glioblastoma multiforme. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 138, 111461	7.5	10
22	Precision delivery of liquid therapy into the arterial wall for the treatment of peripheral arterial disease. <i>Scientific Reports</i> , 2021 , 11, 18676	4.9	0
21	Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer. <i>Gynecologic Oncology</i> , 2021 , 162, 619-625	4.9	1
20	A simple and reliable reverse-phase high-performance liquid chromatographic procedure for determination of paclitaxel (taxol) in human serum. <i>Therapeutic Drug Monitoring</i> , 1997 , 19, 327-32	3.2	16

19	Biological and clinical characterization of paclitaxel polyglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. <i>International Journal of Nanomedicine</i> , 2006 , 1, 375-83	7.3	102
18	Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. <i>Therapeutics and Clinical Risk Management</i> , 2005 , 1, 107-14	2.9	55
17	Role of Cytochrome P450 in Prostate Cancer and its Therapy. <i>Current Enzyme Inhibition</i> , 2020 , 16, 63-73	0.5	3
16	Differential activity of caspase-3 regulates susceptibility of lung and breast tumor cell lines to Paclitaxel. <i>The Open Biochemistry Journal</i> , 2008 , 2, 121-8	0.9	5
15	Carotid artery infusions for pharmacokinetic and pharmacodynamic analysis of taxanes in mice. <i>Journal of Visualized Experiments</i> , 2014 , e51917	1.6	4
14	Drug Interaction between Ketoconazole and Paclitaxel in Rats. <i>Journal of Korean Pharmaceutical Sciences</i> , 2003 , 33, 223-227		
13	Pharmacokinetic Interaction between Diltiazem and Paclitaxel in Rats. <i>Journal of Korean Pharmaceutical Sciences</i> , 2003 , 33, 299-304		
12	DRUGS USED IN CANCER CHEMOTHERAPY. 2010 , 1-229		
11	T. 1998 , 305-336		
10	Principles of Chemotherapy in Older Adults. 2019 , 1-20		
9	Principles of Chemotherapy in Older Adults. 2020 , 861-880		
8	Multi-kinase targeted therapy as a promising treatment strategy for ovarian tumors expressing sfRon receptor. <i>Genes and Cancer</i> , 2020 , 11, 106-121	2.9	1
7	Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer.. <i>Cancer Treatment and Research Communications</i> , 2022 , 30, 100514	2	1
6	Clinical Utility and Analytical Aspects of Direct Measurements of Free Hormones Using Mass Spectrometry-Based Methods.. <i>journal of applied laboratory medicine, The</i> , 2022 ,	2	
5	Loco-regional radiosensitizing nanoparticles-in-gel augments head and neck cancer chemoradiotherapy.. <i>Journal of Controlled Release</i> , 2022 ,	11.7	0
4	Cytochrome P450 enzymes: Novel options for cancer therapeutics. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 363-371	6.1	74
3	Paclitaxel exposure-toxicity analysis reveals a pharmacokinetic determinant for dose-limiting neutropenia in East-Asian solid tumor patients: results from two prospective, phase II studies. 2022 , 90, 229-237		
2	Paclitaxel and Curcumin as Dual-Drug-Loaded Lipid Nanocapsules in the Management of Brain Tumour.		0

- 1 Dual drug-loaded PLGA fibrous scaffolds for effective treatment of breast cancer in situ. **2023**, 148, 213358 ○